Anson Funds Management’s Arbutus Biopharma ABUS Stock Holding History

Anson Funds Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-105,085	Closed	-$257K	–	47
2016 Q4	$257K	Buy	+105,085	New	+$306K	0.08%	69
2015 Q4	–	Sell	-25,000	Closed	-$152K	–	97
2015 Q3	$152K	Hold	25,000	–	–	0.04%	57
2015 Q2	$297K	Hold	25,000	–	–	0.14%	43
2015 Q1	$437K	Buy	+25,000	New	+$512K	0.39%	34

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Anson Funds Management's ABUS Position: Q1 2017 in Review

Anson Funds Management sold out of Arbutus Biopharma (ABUS) in Q1 2017, closing a stake of 105,085 shares — an estimated $257K sold.

Anson Funds Management first reported a position in ABUS in Q1 2015 and held it in 4 quarters. The position peaked at $437K in Q1 2015. 53 funds tracked by Wall St. Rank hold ABUS as of Q1 2017.

Anson Funds Management reported no remaining Arbutus Biopharma position as of Q1 2017 after selling out during the quarter.
Anson Funds Management sold 105,085 Arbutus Biopharma shares in Q1 2017, an estimated $257K.
Anson Funds Management first reported a position in Arbutus Biopharma in Q1 2015 and held it in 4 quarters.
Anson Funds Management's Arbutus Biopharma position peaked at $437K in Q1 2015.
53 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2017.

Based on Anson Funds Management's 13F filing for Q1 2017, filed 15 May 2017.